<p></p> Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. <p></p> The fifth volume of the series covers the following topics: <p></p> -The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors <p></p> -The Role of SGLT2i in the Prevention and Treatment of Heart Failure <p></p> -Natural Products and Semi-Synthetic Compounds as Antithrombotics: A Review of the Last Ten Years (2009-2019) <p></p> -Transient Receptor Potential Channels: Therapeutic Targets for Cardiometabolic Diseases? <p></p> -Treatment of Raynaud’s Phenomenon <p></p> -Traditional Medicine Based Cardiovascular Therapeutics <p></p> -Cardiovascular Disease: A Systems Biology Approach

Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. Volume 6 covers the following topics: - Cardiovascular effects of ranolazine and the scope for translational research: a current review of literature - Rho/Rho kinase signaling pathway and disease: - Hibernation or transformation? Challenges in cardiovascular drug development - New approaches in P2Y12 receptor blocker drugs use - Pathophysiological links between diabetes and cardiovascular diseases: at the biochemical and molecular levels

Advances in Cancer Drug Targets is an e-book series that brings together recent expert reviews published on the subject with a focus on strategies for synthesizing and isolating organic compounds and elucidating the structure and nature of DNA. The reference work serves to give readers a brief yet comprehensive glance at current theory and practice behind employing chemical compounds for tackling tumor suppression, DNA site specific drug targeting and the inhibition of enzymes involved in growth control pathways. The reviews presented in this series are written by experts in pharmaceutical sciences and molecular biology. These reviews have been carefully selected to present development of new approaches to anti-cancer therapy and anti-cancer drug development. This e-book volume will be of special interest to molecular biologists and pharmaceutical scientists.

Advances in Cancer Drug Targets is an e-book series that brings together recent expert reviews published on the subject with a focus on strategies for synthesizing and isolating organic compounds and elucidating the structure and nature of DNA. The reviews presented in this series are written by experts in pharmaceutical sciences and molecular biology. These reviews have been carefully selected to present development of new approaches to anti-cancer therapy and anti-cancer drug development. The contents of this book include chapters on heat shock protein 90, spindle assembly checkpoint, ErbB receptors, anti-tumor effects of bisphosphonates, biomarkers for risk assessment and prevention of breast cancer, fibrates action in Daunorubicin chemical reaction and many more. The reference work serves to give readers a brief yet comprehensive glance at current theory and practice behind employing chemical compounds for tackling tumor suppression, DNA site specific drug targeting and the inhibition of enzymes involved in growth control pathways. This e-book volume will be of special interest to molecular biologists and pharmaceutical scientists.

Advances in Cancer Drug Targets is an e-book series that brings together recent expert reviews published on the subject with a focus on strategies for synthesizing and isolating organic compounds and elucidating the structure and nature of DNA. The reviews presented in this series are written by experts in pharmaceutical sciences and molecular biology. These reviews have been carefully selected to present development of new approaches to anti-cancer therapy and anti-cancer drug development. The contents of this volume include reviews on mediating or inhibiting different signaling pathways such as WNT signaling and MTOR as well as novel drug targets for tumor control such as neutrophil elastase and estrogen sulfatase. These reviews provide updates on new ways to treat a variety of cancers. The reference work serves to give readers a brief yet comprehensive glance at current theory and practice behind employing chemical compounds for tackling tumor suppression, DNA site specific drug targeting and the inhibition of enzymes involved in growth control pathways. This e-book volume will be of special interest to molecular biologists and pharmaceutical scientists.

Brain Tumor Targeting Drug Delivery Systems: Advanced Nanoscience for Theranostics Applications is a comprehensive reference focused on the latest advancements in nanotechnology for brain tumor therapy. With practical insights and cutting-edge research, this book equips readers with the knowledge to develop innovative drug delivery systems for effective brain tumor diagnosis and treatment. Structured into insightful chapters, this book covers the anatomy, physiology, and pathophysiology of the brain, addressing barriers to targeted drug delivery strategies. Chapters explore theranostics-based delivery systems, including polymeric nanoparticles, liposomes, dendrimers, nanoemulsions, micelles, and inorganic nanoparticles, for precise brain tumor diagnosis and treatment. This informative resource is designed for students and research scholars in pharmacology, pharmaceutical industry scientists, professors, and clinical medicine researchers. With comprehensive chapters and references for further reading, this book facilitates easy understanding of the intricate nanomedical technology, empowering researchers to make significant strides in the field of brain tumor therapy. Key Features: - Structured chapters for easy understanding of nanotechnology concepts - In-depth coverage of theranostics-based delivery systems for brain tumor diagnosis and treatment - References for further reading and exploring new advances in drug delivery systems

The book summarizes the role of multiple enzyme targets and strategies to design and develop novel drug candidates for Alzheimer's disease (AD). Insights from researchers across the globe from diverse fields are presented in a thematic volume. The chapters highlight current information scientists have unraveled about the origin, pathogenesis and prevention of AD. The contributions consider both established and emerging drug targets viz. Tau proteins, TREM, and microglia. Topics covered in the book include multi-target anti-Alzheimer's agents, epigenetic modifications, and the role of specific proteins like TMP21 and Tau in AD. A section dedicated to pharmacological treatments discusses the significance of tubulin-modifying enzymes, memantine, and glutamate antagonists. Enzymatic targets for drug discovery are thoroughly examined, focusing on cholinesterase, secretases, and other enzymes. Additionally, the book explores innovative nano-carrier-based drug delivery methods, emphasizing the crucial role of nanotechnology in effective Alzheimer's treatment. The book aims to inform students and researchers in the field of neuroscience, medicine and pharmacology about current research and biochemical nuances of AD pathogenesis and enzymatic drug targeting strategies.

This 2-part reference informs readers about the application of drug delivery technologies to herbal medicines. Chapters cover a broad range of major topics on the subject of targeted drug delivery systems. These topics include the application of drug delivery systems for herbal nanomedicines, drug development issues, emerging technologies, adaptations for clinical use, market prospects and challenges of industrial commercialization. Chapters have been contributed by several experts in pharmaceutical chemistry and blend theoretical knowledge with practical aspects of drug delivery. Part I covers the following topics: - Introduction to nanotechnology and herbal-based nanoparticulate systems - Nucleic acid-based therapeutic drug delivery systems - Herbal bioactives: a booster dose for advanced pharmaceutical nanoscience - Pulmonary nano-drug delivery systems - Application of nano-drug delivery systems in improving the therapeutic efficacy of bioactive natural products - PEGylated liposomes - Insulin liposomes - Aquasomes: a promising novel drug carrier - Nanoparticle-aided herbal drugs: therapeutic implications on cholinergic dysfunction with relevance to Alzheimer's disease - Vitamins based nanomedicine approach - Recent advances in tumor targeting drug delivery systems: fundamentals of advanced pharmaceutical nanoscience - Niosomes: a revolutionary progress in the field of pharmaceutical sciences - Infectious diseases: pharmaceutical nanoscience for targeted drug delivery

This 2-part reference informs readers about the application of drug delivery technologies to herbal medicines. Chapters cover a broad range of major topics on the subject of targeted drug delivery systems. These topics include the application of drug delivery systems for herbal nanomedicines, drug development issues, emerging technologies, adaptations for clinical use, market prospects and challenges of industrial commercialization. Chapters have been contributed by several experts in pharmaceutical chemistry and blend theoretical knowledge with practical aspects of drug delivery. Part II covers the following topics: - Pharmaceutical nanosciences and their application in the delivery of various phytoconstituents - Design of cosmeceutical drug delivery systems: the role of nanotechnology in cosmeceuticals - Transfersomes: a novel vesicular transdermal delivery system - Self-nano/micro emulsified drug delivery systems - Phytosomes - The role of nanomedicines in ocular drug delivery systems - Colloidosomes as an efficient novel drug delivery system: an update - Herbal nanoscience: challenges and regulatory perspectives - Vitamins based nanomedicine approach - Dendrimers: a versatile nanoplatform for advanced targeting and bioactive(s) delivery - Targeted drug delivery systems for cells and cell organelles - Liposomes for herbal drug delivery - AI in pharmacy, herbal medicine and drug delivery: sci-fi or reality?

Biotechnology and Drug Development for Targeting Human Diseases is an insightful compendium on drug development technologies for professionals and students in biotechnology and pharmacology. This book meticulously explores the intersection of biotechnology with drug development, emphasizing its crucial role in creating new therapies for human disease. Central to the book is the innovative use of biotechnology in understanding and treating diseases. It begins with an exploration of multi-omics profiles, shedding light on disease mechanisms and drug development. Subsequent chapters explain in silico methods for drug design, the role of natural products in antimicrobial applications and wound healing, and the use of viruses as carriers in biotechnology. Key features of this reference include a blend of theoretical knowledge and practical insights, detailed analyses of molecular docking in drug discovery, the repurposing of drugs for various diseases, and the emerging field of omics technologies in drug interaction studies. Each chapter is comprehensive, offering current information backed by extensive references, making the book both a foundational and advanced resource.